Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Dec;40(12):2760-4.
doi: 10.1128/AAC.40.12.2760.

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA

Affiliations

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA

C Janoir et al. Antimicrob Agents Chemother. 1996 Dec.

Abstract

The mechanism of high-level fluoroquinolone resistance was studied in strains of Streptococcus pneumoniae, either selected in vitro or isolated from clinical samples. By using DNA from these high-level-resistant strains, low-level-resistant transformants (MIC of pefloxacin, > or = 32 micrograms/ml; MIC of ciprofloxacin, 4 micrograms/ml; MIC of sparfloxacin, 0.50 micrograms/ml) were obtained at high frequencies (ca.10(-2)), while high-level-resistant transformants (MIC of pefloxacin, > or = 64 micrograms/ml; MIC of ciprofloxacin, 16 to 64 micrograms/ml; MIC of sparfloxacin, > or = 8 micrograms/ml) were obtained only at low frequencies (ca.10(-4)). This suggested that mutations in at least two unlinked genes were necessary to obtain high-level resistance. Low-level resistance was associated with ParC mutations (change from Ser to Tyr at position 79 [Ser79Tyr], Ser79Phe, or Asp83Gly). ParC mutations were associated, in high-level-resistant strains and transformants, with alterations in the quinolone resistance-determining region of GyrA (Ser84Tyr, Ser84Phe, and/or Glu88Lys). Low-level resistance was shown to be necessary for expression of the gyrA mutations. No mutation in the region corresponding to the quinolone resistance-determining region of GyrB and no alteration of drug accumulation were found.

PubMed Disclaimer

References

    1. J Bacteriol. 1996 Jul;178(14):4060-9 - PubMed
    1. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):304-15 - PubMed
    1. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3541-5 - PubMed
    1. Chemotherapy. 1993;39(1):36-9 - PubMed
    1. J Bacteriol. 1992 Mar;174(5):1596-603 - PubMed

Publication types

LinkOut - more resources